With the initiation of this study, Orexo advances its strategic goal to expand into respiratory and allergy-related conditions, diversifying its product pipeline beyond its established work in addiction medicine. The success of OX640 could position Orexo as a competitive player in the allergic rhinitis market, particularly given the rising global demand for effective, rapid allergy treatments. Robert Rönn, SVP and Head of R&D, said: "Anaphylaxis is a serious and life-threatening condition, making it essential to ensure that OX640 remains effective even in the presence of nasal allergic symptoms. The study addresses key development and regulatory requirements and is an important step in advancing the project towards regulatory approval. The performance of OX640 under allergic rhinitis conditions has also been requested in many discussions with health care providers and with potential partners."